Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-23, Stock:NVS, The news for the past five days is as follows:
2019-05-16: NEWS1: Tilray Stock Is Red-Hot, But It’s Fundamentally Flawed.NEWS2: Three Conservative Ways to Play Cannabis.
2019-05-17: NEWS1: Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock.NEWS2: Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model.NEWS3: Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure.NEWS4: Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure.NEWS5: GSK and Novartis liniment marketing misled Australian consumers - court.
2019-05-20: NEWS1: Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study.NEWS2: Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study.NEWS3: Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study.NEWS4: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS5: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS6: Ligand Grants Preclinical Candidate Rights to UK-based Firm.NEWS7: Ligand Grants Preclinical Candidate Rights to UK-based Firm.NEWS8: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS9: Ligand Grants Preclinical Candidate Rights to UK-based Firm.
2019-05-21: NEWS1: Cramer Remix: The cannabis stocks I&apos;m eyeing.NEWS2: Cramer Remix: The cannabis stocks I'm eyeing.NEWS3: Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO.NEWS4: Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO.NEWS5: Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches.NEWS6: Novartis CEO calls for fixing &apos;distortions&apos; in health care system ahead of slate of drug launches.NEWS7: Here's Why Array BioPharma Is Surging Today.NEWS8: Here's Why Array BioPharma Is Surging Today.NEWS9: These 3 Major Drug Manufacturers Are Strong Performers.NEWS10: Novartis CEO says cannabis isn&apos;t a focus despite Tilray partnership.NEWS11: Novartis CEO says cannabis isn't a focus despite Tilray partnership.NEWS12: Novartis CEO on single-payer health care: It is not the right move for America.NEWS13: Validea Peter Lynch Strategy Daily Upgrade Report - 5/21/2019.NEWS14: Validea Peter Lynch Strategy Daily Upgrade Report - 5/21/2019.
2019-05-22: NEWS1: Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range.NEWS2: Novartis CEO plans gene therapy price 'far lower' than $4 mln to $5 mln range.NEWS3: Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point.NEWS4: The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study.NEWS5: 3 Bearish Takeaways From the Tilray Earnings Report.NEWS6: 3 Bearish Takeaways From the Tilray Earnings Report.

Answer: Rise